In previous systematic reviews (predominantly of randomized controlled trials), pulmonary rehabilitation (PR) has been shown to reduce hospital admissions for acute exacerbations of COPD (AECOPD). However, findings have been less consistent for cohort studies. The goal of this study was to compare rates of hospitalized and general practice (GP)-treated AECOPD prior to and following PR.
Given the evidence of these benefits, a recent Cochrane editorial stated that no further systematic reviews are required to show that PR improves patient-related outcomes. 10 A recent update in a 2016 systematic review by Puhan et al 11 found that PR reduced hospital readmissions, but the results were heterogeneous, and the evidence did not show a statistically significant effect of rehabilitation on mortality. Results from randomized controlled trials (RCTs) in another recent review suggested that PR reduces subsequent readmissions, but pooled results from cohort studies and before-and-after studies did not. 12 Therefore, the evidence for the benefits of PR on reducing hospital admissions remains unclear.
Furthermore, no study has investigated the effect of PR on reducing hospital admissions or milder general practice (GP)-treated events, particularly in patients with less severe COPD; arguably, these patients are the ones who comprise the majority of referrals for PR. This fact is important because GP-managed exacerbations have been associated with declines in exercise capacity and muscle strength, and reduced physical activity can affect quality of life. 13 The present study aimed to compare the rates of hospitalized and GP-treated AECOPD prior to and following PR by using primary care data from the UK Clinical Practice Research Datalink (CPRD), linked with Hospital Episode Statistics (HES). First, exacerbation rates were compared in those who were eligible and referred for PR vs those who were eligible and not referred during all the time observed (Observation 1) (Fig 1) . Second, exacerbation rates were compared prior to and following PR in those who were eligible for PR and were referred over the whole study period (Observation 2). Third, we compared 1 year prior to and 1 year following PR in those who were eligible and were referred (Observation 3). Fourth, we compared exacerbation rates 1 year prior to and 1 year following PR for those who actually completed the course of rehabilitation (Observation 4). Finally, length of stay (LOS) was examined for those who were hospitalized for AECOPD at least once in the year prior to and the year following rehabilitation. chestjournal.org
Patients and Methods

Study Subjects
Patients aged > 35 years who had a GP-recorded diagnosis of COPD using a validated definition 14 and who did not have a 1 -antitrypsin deficiency but had at least 1 year of historical data prior to the study start were included. Patients were deemed eligible for PR if they had a PR code that suggested they were eligible (e-Appendix 1 includes the code list), or if they had a Medical Research Council (MRC) score $ 3, or if they had $ 2 GP-treated AECOPD in 1 year or one hospital admission for an AECOPD in 1 year. This definition was based on current clinical practice for referral. 15 A previously validated definition was used to identify AECOPD in CPRD and HES. 16, 17 Institutional review board approval was not required because this study used anonymous patient data. Prior to study start, approval was obtained from the CPRD Independent Scientific Advisory Committee, which oversees research involving CPRD data (protocol ref: 15_193R; available on request).
Study Design
This propensity-weighted cohort study also included a before-and-after analysis. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines 18 were used in this study.
Methods
CPRD is an electronic database of UK general practice data that has been widely used for research. 19 It contains anonymized records for > 13 million patients, 4.4 million of whom are currently registered with a practice that is contributing data to CPRD, representing about 9% of the UK population. Data held include information on consultations, diagnoses, tests, referrals to secondary care, and prescriptions from primary care as well as some lifestyle data. Data are predominantly recorded using a system of "Read Codes," a hierarchical system of codes that includes diagnoses, clinical signs, symptoms, and lifestyle characteristics. Approximately 60% of the patients included in the CPRD have been linked to HES, an administrative database containing information on all episodes of National Health Service inpatient care in England. 16 Diagnoses in HES are recorded by using International Classification of Diseases, 10th Revision, codes (e-Appendix 1). Figure 1 presents the study design and the four main observation periods. The date of entry into the cohort was the latest of January 1, 2004, the diagnosis of COPD, and the date of being eligible for (or undergoing) PR. The end of follow-up was the earliest of the end of the study period (March 31, 2014), the last date of data collection, the date of death, or the date of transfer to another practice. Control subjects (patients with COPD not referred for rehabilitation) were age-, sex-, and CPRD practice-matched to patients with COPD who were referred for PR. The date of referral for rehabilitation was the index date for the match. Patients were deemed eligible for PR if they had an MRC score $ 3, had $ 2 GP exacerbations in a 1-year time period, or had one hospital admission for an AECOPD in 1 year. Patients were considered ineligible if they had cerebrovascular disease, rheumatoid arthritis, depression, heart failure, or stroke.
Analysis
Baseline characteristics were tabulated and c 2 tests performed to test the association between the PR status and categorical explanatory variables. Exacerbation rates of AECOPD were compared in the year prior to and 1 year following PR, only on patients who were ever referred for rehabilitation. Recorded visits to the GP for an exacerbation and hospital visits were analyzed separately and then in combination for patients who were recorded as having PR and compared with patients who were eligible but were not referred for PR. Hospital LOS was also analyzed in patients who were eligible and referred for PR in the year prior to and year following PR according to the Wilcoxon signed-rank test. Statistical calculations were conducted by using STATA version 14 (StataCorp). 20 The observation period for each patient was defined as an interval of time at risk between two successive dates (beginning on the first event date and ending on the day prior to the last event date). An event date could be an imputed patient birthday (July 1 on any year from the patient birth year), date of patient entry to observation by CPRD, date of patient exit from observation by CPRD, date of initiation of PR, date 1 year prior to initiation, date 1 year following initiation, or date of diagnosis of one of the following diseases: COPD, asthma, cerebrovascular disease, rheumatoid arthritis, depression, heart failure, or stroke. The outcomes were numbers of AECOPD reported by the patient's GP (determined in CPRD), numbers of COPD exacerbations leading to hospitalizations (determined in HES and excluding elective admissions), and total numbers of both, in the duration of observation for that patient. We used Poisson generalized linear models, with exposure time at risk expressed in person-years, and Huber variances clustered according to practice. Analyses were performed on four subsets of observation periods and are listed in e-Appendix 1.
Propensity weights were calculated by using a propensity score from a logistic regression model, with Huber variances clustered according to practice, with PR treatment as the outcome and confounding covariates as the predictors. Methods for the propensity scoring and list of confounders are described in e-Appendix 1. Figure 2 displays the flow of subjects included, and Table 1 describes the baseline demographic characteristics and comorbidities of patients included in the analysis. A total of 108,041 patients were included; 53% were male. A total of 38,953 (36%) patients with COPD were not eligible for PR (ie, they did not meet our eligibility criteria). Of the 69,089 eligible patients, 6,436 (9.3%) were recorded as having been referred to or completed PR, 62,019 (89.8%) were not referred, and 634 (0.9%) were referred but declined referral. The mean AE SD age of patients who received rehabilitation was 64.53 AE 10.17 years. Table 2 provides the baseline respiratory-related characteristics of the patients with COPD. The average follow-up time for all eligible patients was 3.29 years, and for those eligible and referred for PR, it was 4.57 years.
Results
Exacerbation Rates in Patients With COPD Referred for PR vs Those Not Referred (Observation 1) Figure 3 and Table 3 show the following: (1) the exacerbation rate per person-year at risk and the Figure 4 and AECOPD rates per person-year at risk (95% CI) 1 year prior to and 1 year following initiation of PR are shown Figure 3 -A, Exacerbation rate per person-year at risk (95% CI) comparing patients who were eligible for PR and not referred vs patients who were eligible and referred during the study period. B, Exacerbation rate ratio (95% CI) in unweighted and propensity-weighted analyses comparing patients eligible and not referred for PR vs patients eligible and referred for PR during the study period. GP ¼ general practice. See Figure 1 legend for expansion of other abbreviation.
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in Figure 5A . The same trend was observed in the before-and-after comparison in each analysis as observed in Figure 4 . Figure 5B shows the exacerbation rate ratio (95% CIS) in unweighted and propensity-weighted analyses comparing 1 year prior to and 1 year following PR. Higher exacerbation rate ratios were observed in primary care compared with hospital events. Table 5 provides the detailed scores for exacerbation rates per person-year at risk observed in the before-and-after analysis. Figure 6A shows the exacerbation rate per person-year at risk (95% CIs) 1 year prior to and 1 year following PR in patients who completed rehabilitation; the scores are displayed in Table 6 . In addition, Figure 6B shows the exacerbation rate ratio (95% CIs) in unweighted and propensity-weighted analyses comparing patients completing PR 1 year prior to and 1 year following PR. 
Hospital LOS
When looking at hospital LOS in a subset of 305 patients who were hospitalized for AECOPD at least once in the year prior to and once in the year following rehabilitation, there was no reduction in the median LOS following PR. Figure 7 shows that the median LOS 1 year prior to rehabilitation was 4 days (interquartile range, 2-8 days) compared with 1 year following rehabilitation in which the median LOS was 7 days (interquartile range, 3-18 days).
Discussion
Less than 10% of patients with COPD in the United Kingdom who were eligible for PR in the present study were actually referred. Patients who were eligible and referred for PR from primary care did not have fewer GP visits or hospital admissions for AECOPD 1 year after rehabilitation compared with those who were eligible but were not referred. The same trend was observed when comparing exacerbation rates in 1 year prior to and 1 year following rehabilitation in those eligible and referred and limiting the analysis to a subset of patients who had evidence of having completed PR. This approach agrees with more recent studies that have shown no benefit of rehabilitation on hospital readmissions. 11 When comparing GP exacerbations with hospital exacerbations, COPD exacerbation severity did not seem to be reduced in the year following PR. Furthermore, we found no reduction in hospital LOS for exacerbations of COPD prior to and following PR. 
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One of the key strengths of this study is that it included a large cohort of patients with COPD examined over a long period of time with exacerbation data from both primary and secondary care. In addition, the data used are from routinely collected primary care and hospital sources, reflecting real-life patients seen in everyday clinical practice. It was a large cohort study, and the results are similar to those of other studies, including a retrospective cohort study in California by Nguyen et al 21 that compared rates of exacerbations in 558 patients who received PR in the stable state vs 1,114 patients who did not. Twelve months after the program, 10% of the nonintervention group were hospitalized for an exacerbation, whereas 18% of the PR group were hospitalized.
The present study has several weaknesses, however, which might explain the differences between these findings and those of systematic reviews and some RCTs. First, records from CPRD and HES may not be a complete and accurate reflection of what patients with COPD are actually experiencing because not all patients receiving PR will be recorded by clinicians and captured in electronic health records. Indeed, in this study, < 10% of patients with COPD who were eligible were referred. Second, we have not analyzed compliance with rehabilitation but only investigated patients who were captured as having been referred for PR. Because only approximately 40% of people referred for PR complete a course, 22 the lack of benefit seen here is likely to be underestimated. Another weakness of using electronic health data is that we were not able to examine the nature of the PR program that patients were referred to (eg, the number of sessions, the intensity and content of the rehabilitation) to compare them vs UK standards and guidelines. We are aware that patients may have been referred to PR via other sources and thus not captured as having been referred in this dataset but given the nature of health-care provision in the United Kingdom with the GP at the center, this scenario is likely to be minimal. Certainly of those referred, a higher proportion are likely to have completed PR than has been recorded, and improved coding of completion of PR (for which Read Codes do exist) would aid commissioners and PR providers in determining the effects and benefits of PR.
One of the reasons why the results from our study differed from those of RCTs is that patients in the RCTs completed the course of PR and may have had greater compliance, and thus the effectiveness of PR on reducing admission may be greater. Another issue is that PR programs vary significantly, and although guidelines for PR programs exist, 15 differing interpretations of these guidelines can occur in routine practice, and thus programs may vary between centers across the country. 22 As previously mentioned, we were not able to assess the content and quality of the PR program.
Another important consideration is how education within a rehabilitation program is delivered to and received by patients. One study that randomized patients into a comprehensive care management plan vs usual care found that mortality was higher in the comprehensive care management plan group. 23 This group received COPD education on self-management and an action plan for identification and treatment of their exacerbations. The higher mortality figure suggests that despite having education about self-management, some patients still do not seek advice and treatment early enough to reduce exacerbations or, conversely, that they become more vigilant and aware of their symptoms. 
Finally, the severity of COPD for patients with the disease who are eligible for PR also differs, and this factor may also have contributed to the lack of exacerbation reduction. However, when we restricted the analysis to hospital events only, we still did not see a reduction in exacerbations. There may be unobserved confounding despite propensity matching. Reductions in LOS following rehabilitation have also been reported in some RCTs 24, 25 and observational studies, 26 whereas a reduction in LOS was not observed in this cohort.
Reasons for this finding may include the fact that patients in our analysis were older and frailer and possibly had more comorbidities than those who participated in the RCTs. Furthermore, we only considered hospitalizations for AECOPD and did not include other causes of hospitalizations.
There are a number of potential biases that might affect recorded exacerbation rates between the various comparator groups in our study, particularly confounding by indication (ie, those presenting with exacerbations are more likely to be referred) and the impact of attendance on health behaviors in which the provision of education during PR might actually increase because of a heightened awareness of treatment need. In addition, variations in exacerbation frequency over time may have had an impact on the year-to-year comparison in those referred for PR.
Our study and several other observational studies have not replicated the findings from RCTs and our recent systematic review, 12 which have suggested that PR is effective at reducing the frequency of exacerbations; however, a reduction in AECOPD has been observed in RCTs of PR postexacerbation. RCT programs may have more effective content, delivery, follow-up, and motivation than standard rehabilitation courses. Surveys have suggested that the provision of PR services can vary chestjournal.org both within and between countries. 27 This finding highlights the need for PR courses to be accredited and able to demonstrate adherence to the standards found in RCTs to be of maximum benefit to patients. This study also highlights the need for GPs to record completers of PR for measurement of more accurate and meaningful outcomes.
PR has many other benefits aside from reducing healthcare consumption and exacerbations. Although there is no convincing biologic rationale to suggest that PR will reduce the frequency of lung events, there is evidence that early PR following an exacerbation can lead to a reduced number of days spent in the hospital. 25 Numerous studies have also shown that PR improves health-related quality of life, activity limitation, perceived breathlessness, and exercise capacity. 28, 29 These improvements may be arguably more important to patients who experience COPD than reducing healthcare consumption, and thus PR remains an important intervention to patients.
Despite these findings, PR is still underused. 30, 31 Major challenges in realizing the effectiveness of PR are that a proportion of people who have COPD and hence AECOPD have not been diagnosed, 32 and a large proportion of those who have been diagnosed and are eligible for PR are not being referred. 22 In addition, the England and Wales national COPD audit program, which includes data from both the acute hospital settings and primary care, reported that 31% of patients referred for rehabilitation did not attend the initial assessment, and 40% of those referred did not complete the program. 22, 33 A small proportion of individuals are offered PR following an AECOPD but even fewer will take up a course. 34 Although we are likely to have overestimated the number of eligible but not referred people in this dataset (because we cannot account for the main reasons people may not be eligible), our findings are in keeping with the UK PR audit data. 22 Further research is needed to look at reasons why patients with COPD who are eligible for PR are not being referred, reasons why those who are being referred are not completing programs, and the effect on readmissions. Previous studies have suggested that current smoking, a lack of perceived benefit, and depression are all likely to represent barriers to uptake or increase noncompletion. 35 
Conclusions
Using data from primary care and hospital records, this study found that patients who were referred for PR did not have fewer GP and hospital AECOPD 1 year following PR compared with those who were not referred. Any effect of PR on exacerbation frequency was not detectable through routinely recorded primary care data. Findings from our study, along with results from other studies and audit data, have highlighted a major clinical issue in that large proportions of patients are either not starting PR or are not completing PR. As an intervention, PR has great potential to be effective if patients are referred and can adhere to a properly designed and delivered program. Future research assessing the effects of PR on GP and hospital visits for COPD should take into account the important issues relating to the referral of patients and adherence to a program, and the national COPD audit should monitor the content of rehabilitation more closely. 
